Ranbaxy CFO quits 6 months after CEO exit

More turmoil for India's Ranbaxy Laboratories. CFO Omesh Sethi has left the company, becoming the third top executive to do so since its Japanese majority owner took control. Moreover, Sethi is leaving only six months after CEO Atul Sobti took a hike, saying his vision for the company didn't mesh with Daiichi's.

Daiichi confirmed Sethi's departure to Bloomberg, but wouldn't comment beyond that. Ranbaxy didn't offer a reason for the change, just saying it was effective Tuesday.

It's rarely a good time to lose two top managers in quick succession. As CLSA Asia-Pacific Markets analyst Hemant Bakru told Bloomberg, "You lose that continuity which is essential for any corporation to run well." But needless to say, it's an especially bad time for Ranbaxy. Two years into an import ban, the company is still trying to mend its relationship with FDA. Constrained in the important U.S. market, Ranbaxy's sales have suffered; for 2009, its most recent full-year results, sales grew by only 2.5 percent.

- read the Reuters story
- check out the coverage from Bloomberg

Suggested Articles

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

A new NEJM study found taking hydroxychloroquine after COVID-19 exposure doesn't reduce the risk of an infection. But questions remain.